Skip to main content

Table 1 Baseline characteristics

From: Final results of a phase I/II pilot study of capecitabine with or without vinorelbine after sequential dose-dense epirubicin and paclitaxel in high-risk early breast cancer

  Overall population
(n = 51)
Dose level 1
(n = 10)
Dose level 2
(n = 11)
Dose level 3
(n = 26)
Dose level 4
(n = 4)
Median age, years (range) 53 (32-67) 49 (37-64) 49 (32-64) 55 (35-67) 56 (49-56)
ECOG performance status (%)      
   0 80 80 82 88 25
   1 20 20 18 12 75
Tumour stage (%)      
   1 25 40 18 23 25
   2 67 60 82 62 75
   3 6 0 0 12 0
   4 2 0 0 4 0
Nodal stage (%)      
   1 10 0 18 12 0
   2 53 60 45 54 50
   3 37 40 36 35 50
Involved lymph nodes      
   Median number 9 10 9 7.5 7.5
   3-6* (%) 39 20 45 42 50
   7-9 (%) 20 30 9 23 0
   10-14 (%) 20 10 27 19 25
   15-19 (%) 12 20 9 8 25
   ≥20 (%) 10 20 9 8 0
Hormone receptor status (%)      
   ER or PgR positive 76 80 64 77 100
   ER and PgR negative 24 20 36 23 0
HER2 status (%)      
   Positive 33 40 27 27 75
   Negative 63 60 64 69 25
   Unknown 4 0 9 4 0
  1. *One patient had only three involved nodes but was included in all analyses
  2. ECOG, Eastern Cooperative Oncology Group, ER, oestrogen receptor, PgR, progesterone receptor